Regulatory T-Cell Activity Analysis
We provide detailed analysis of Treg function, including their capacity to suppress immune responses and maintain tolerance. Our studies offer key insights into Treg-mediated regulation, supporting the development of therapies targeting immune balance and autoimmunity.
CD8+ T Cell and NK Cell-Mediated Lymphotoxicity Analysis
We specialize in evaluating the ability of CD8+ T cells and NK cells to target and eliminate infected or malignant cells, providing critical insights into immune-mediated cytotoxicity. Our studies offer valuable data for the development of immunotherapies that harness the power of CD8+ T cells and NK cells.
Multicellulare Agregates of Lymphoma Cells (MALC)
Explore complex tumor biology with our Multicellular Aggregates of Lymphoma Cells (MALC) model. It mimics the 3D structure and microenvironment of lymphoma, providing a robust system for studying cell-cell interactions, tumor progression, and therapeutic responses. The MALC model enables more physiologically relevant insights compared to traditional 2D cultures, supporting the development of targeted lymphoma therapies.
B-cell lymphoma cell lines
Explore our diverse range of B-cell lymphoma cell lines (PMBL, MCL, FL, DLBCL, BL), including parental and CRISPR- or shRNA-engineered models, and extensively characterized at molecular and phenotypic levels. Our collection also includes EBV-transformed cell lines and drug-resistant lines, supporting research on lymphoma biology, therapeutic targets, and resistance mechanisms.
Drug Testing
We offer robust evaluation of small molecules, antibodies, and CAR-T cells to accelerate therapeutic discovery and development. Utilizing state-of-the-art cell culture techniques, our platform accommodates diverse experimental needs across various models, including cell lines, primary cells sourced from patients, PDX models, and in vivo mouse models.
Exome-seq
Based on our Exome-seq technology, which sequences all protein-coding regions, we provide detailed genetic profiling of patient cell to uncover disease mechanisms and potential therapeutic targets in lymphoid neoplasms.
In Ovo Patient Derived Xenographt (AVI-PDX)
Explore our InOvo PDX models to investigate lymphoma biology, identify novel drug targets and testing for drug efficacy and toxicity.
Mapping the Epigenetic Landscape: ChIP-seq, CUT&Run, and CUT&Tag
Our epigenetics methodologies, including Chromatin Immunoprecipitation (ChIP-seq), CUT&Run and CUT&Tag, provide new insights into the regulatory mechanisms governing gene expression and chromatin structure. It allows researchers to dissect complex regulatory networks, identify novel transcriptional regulatory elements, and uncover the molecular basis of diseases.
Mouse Cell line Derived Xenographt (Mouse-CDX)
Explore our Mouse CDX models (parental and CRISPR-Cas9 engineered) to investigate lymphoma and Multiple Myeloma biology, identify novel drug targets and testing for drug efficacy and toxicity.
Multiple Myeloma cell lines
Explore our panel of human myeloma cell lines, including parental and CRISPR- or shRNA-engineered models, extensively characterized at molecular and phenotypic levels. Our collection also includes drug-resistant lines, supporting research on multiple myeloma biology, therapeutic targets, and resistance mechanisms